570
Participants
Start Date
June 11, 2018
Primary Completion Date
June 30, 2024
Study Completion Date
December 31, 2024
EV3D Assay
The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
Roswell Park Cancer Institute, Buffalo
Penn State Health, Milton S. Hershey Medical Center, Hershey
Inova Fairfax Hospital, Falls Church
Prisma Health, Greenville
University of California, San Francisco, San Francisco
Oregon Health & Science University, Portland
Veterans Administration Portland Health Care System, Portland
University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock
Capital Health Institute for Neurosciences, Trenton
Lead Sponsor
KIYATEC
INDUSTRY